Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

AbbVie's venetoclax set for early access in UK

AbbVie's venetoclax set for early access in UK

cell receptor pathway inhibitor therapy such as Johnson &Johnson's BTK inhibitor Imbruvica (ibrutinib) or Gilead Sciences' Zydelig (idelalisib).

Latest news

More from news
Approximately 4 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Choosing destiny
As our market transforms, firms must choose their new business model carefully...
Market access improvements in Turkey
...
annual-marketing-summit.jpg
Showcasing our multichannel capabilities in Berlin
Join Anthill for conferences in October to understand how to bring value to HCPs through multichannel communications...

Infographics